ADMA Biologics (ADMA) vs CRISPR Therapeutics (CRSP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CRISPR Therapeutics (CRSP) has outperformed ADMA Biologics (ADMA) over the past year, losing 22.2% versus a loss of 23.3%. Over five years, ADMA leads with a +808.3% price change compared with -50.4% for CRSP. CRISPR Therapeutics is the larger company by market cap ($3.79 billion vs $2.92 billion), about 1.3 times the size, while ADMA Biologics is growing revenue faster (+19.6% vs -90.6%).
ADMA Biologics converts more of its revenue into profit, with a net margin of 28.8% versus -16569.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | CRSP |
|---|---|---|
| Share price | $13.17 | $39.10 |
| Market cap | $2.92B | $3.79B |
| 1-day change | -1.27% | +0.44% |
| YTD return | -27.80% | -25.44% |
| 1-year return | -23.34% | -22.16% |
| 5-year return | +808.28% | -50.37% |
| P/E ratio (TTM) | 17.10 | — |
| Forward P/E | 14.06 | — |
| EPS (TTM) | $0.77 | $-4.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $510.17M | $3.51M |
| Revenue growth (YoY) | +19.63% | -90.59% |
| Net income (latest FY) | $146.93M | $-581.60M |
| Gross margin | 57.39% | — |
| Operating margin | 37.53% | -18933.65% |
| Net margin | 28.80% | -16569.77% |
| 52-week high | $20.46 | $63.45 |
| 52-week low | $7.21 | $38.15 |
| Distance from 52-week high | -35.62% | -38.38% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +36.67% | +118.47% |
| Average volume | 3.23M | 1.74M |
| Shares outstanding | 221.85M | 97.00M |
| Employees | 640 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADMA Biologics is more profitable, keeping 28.8 cents of every revenue dollar as net income versus -16569.8 cents for CRISPR Therapeutics.
- ADMA Biologics grew revenue faster in its latest fiscal year (+19.63% vs -90.59%).
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About CRISPR Therapeutics
CRSP stock →CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
ADMA vs CRSP FAQ
Which is bigger, ADMA Biologics or CRISPR Therapeutics?
CRISPR Therapeutics (CRSP) is larger, with a market capitalization of $3.79B compared with $2.92B for ADMA Biologics (ADMA).
Which stock has performed better over the past year, ADMA or CRSP?
CRSP returned -22.16% over the past 12 months, compared with -23.34% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and CRISPR Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.